Novo Nordisk shares fall on latest trial results for new obesity drug
Participants with type 2 diabetes had an average weight loss of 15.7 per cent after 68 weeks on CagriSema
Full Article
Novo Nordisk shares fall on latest trial results for new obesity drug
FT.com
0 shares
1 views